Amedisys, Inc. (NASDAQ:AMED) Receives Consensus Recommendation of “Hold” from Brokerages

Amedisys, Inc. (NASDAQ:AMED) has earned a consensus rating of “Hold” from the eight research firms that are presently covering the firm, Marketbeat.com reports. Seven analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average 12-month price target among analysts that have covered the stock in the last year is $97.50.

Several research analysts recently weighed in on AMED shares. Raymond James reiterated a “market perform” rating on shares of Amedisys in a research report on Tuesday, March 26th. StockNews.com started coverage on Amedisys in a research report on Monday, April 8th. They set a “buy” rating for the company. Finally, Royal Bank of Canada lifted their price target on Amedisys from $97.00 to $100.00 and gave the company an “outperform” rating in a research report on Monday, March 25th.

Amedisys Price Performance

Shares of AMED stock opened at $91.35 on Tuesday. Amedisys has a 1-year low of $73.10 and a 1-year high of $96.44. The stock’s 50-day moving average is $93.00 and its 200 day moving average is $93.48. The company has a market cap of $2.98 billion, a P/E ratio of -294.67, a PEG ratio of 4.32 and a beta of 0.86. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.05 and a quick ratio of 1.05.

Amedisys (NASDAQ:AMED) last issued its quarterly earnings results on Wednesday, February 21st. The health services provider reported $0.94 earnings per share for the quarter, missing the consensus estimate of $1.04 by ($0.10). Amedisys had a positive return on equity of 12.76% and a negative net margin of 0.44%. The business had revenue of $570.79 million during the quarter, compared to analyst estimates of $566.85 million. During the same period in the prior year, the business posted $1.16 EPS. Amedisys’s revenue was up 1.6% compared to the same quarter last year. Research analysts predict that Amedisys will post 4.54 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Amedisys

A number of institutional investors have recently added to or reduced their stakes in AMED. KBC Group NV purchased a new stake in Amedisys in the fourth quarter valued at $41,000. Neo Ivy Capital Management purchased a new stake in shares of Amedisys in the 2nd quarter valued at $44,000. Covestor Ltd raised its holdings in shares of Amedisys by 88.9% in the 1st quarter. Covestor Ltd now owns 323 shares of the health services provider’s stock valued at $56,000 after buying an additional 152 shares during the period. Banque Cantonale Vaudoise purchased a new stake in shares of Amedisys in the 1st quarter valued at $60,000. Finally, Acadian Asset Management LLC purchased a new stake in shares of Amedisys in the 1st quarter valued at $67,000. Hedge funds and other institutional investors own 94.36% of the company’s stock.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.